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Abstract
Background: Kidney stone matrix protein composition is an important yet poorly understood aspect of
nephrolithiasis. We hypothesized that this proteome is considerably more complex than previous reports have
indicated and that comprehensive proteomic profiling of the kidney stone matrix may demonstrate relevant
constitutive differences between stones. We have analyzed the matrices of two unique human calcium oxalate
stones (CaOx-Ia and CaOx-Id) using a simple but effective chaotropic reducing solution for extraction/solubilization
combined with label-free quantitative mass spectrometry to generate a comprehensive profile of their proteomes,
including physicochemical and bioinformatic analysis.`
Results: We identified and quantified 1,059 unique protein database entries in the two human kidney stone
samples, revealing a more complex proteome than previously reported. Protein composition reflects a common
range of proteins related to immune response, inflammation, injury, and tissue repair, along with a more diverse set
of proteins unique to each stone.
Conclusion: The use of a simple chaotropic reducing solution and moderate sonication for extraction and
solubilization of kidney stone powders combined with label-free quantitative mass spectrometry has yielded the
most comprehensive list to date of the proteins that constitute the human kidney stone proteome.
Keywords: Calcium oxalate, Kidney stone, Label-free quantitative liquid chromatography–tandem mass
spectrometry, Matrix protein, Nephrolithiasis, Proteomics
Background
The organic matrix within urinary stones has long been
thought to be an important—if poorly understood—part
of stone composition. It has been proposed that the
process of stone formation involves the primary depos-
ition of matrix, with crystal formation occurring second-
arily within the matrix layer [1, 2]. Others maintain that
crystallization is primary and that most, if not all, of the
organics in stones are co-precipitated with the crystals
in a manner that is in no way causative [3]. Recent work
on the interface of the growth of calcium oxalate (CaOx)
stones on Randall’s plaque has suggested that matrix
deposition is the primary event, at least in the formation
of CaOx stones over plaque. The first layer covering
plaque that has been exposed to urine is an organic layer
that contains Tamm Horsfall protein, aka uromodulin
[4]. Thereafter, nucleation of apatite begins and depos-
ition of CaOx follows [4].
Progress on characterizing the composition of stone
matrix has been slow, in part because of its insolubility.
The work that has been done also has demonstrated that
the matrix composition is remarkably variable and com-
plex [5]. However, recent studies of human stone matrix
have begun to exploit the power of modern proteomic
methods, with some patterns beginning to emerge in the
kinds of proteins found [6–17]. Nine of these recent
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or crystal-associated proteins [6, 7, 9, 11–15, 17] but
only one study has attempted to quantify them [17].
Thus far, the number of proteins identified in human
stone matrices has been relatively modest, ranging from
30 [11] to 242 [10] distinct proteins identified across a var-
iety of stone mineral types where the proteome has been
investigated. In general, where protein profiles of different
types of stones were compared, differences across stone
types were minimal whereas protein differences within
stone types were quite variable. This is likely due to two
factors: 1) only the most abundant, common proteins
were identified by these studies and 2) individual kidney
stone proteomes are by nature variable and diverse.
We hypothesized that the analysis of human stone
matrix should yield significantly more proteins than pre-
viously detected and that an improved approach may be
useful in studying nephrolithiasis. Using a simple but ef-
fective chaotropic reducing solution for extraction and
solubilization, one that historically works well for a
broad range of protein samples [18–20], combined with
gentle, intermittent sonication, we have analyzed ex-
tracts of two unique human CaOx stones, CaOx-Ia and
CaOx-Id, (of different morphologies of CaOx monohy-
drate, according to the morphoconstitutional classifica-
tion scheme published by Daudon [21]), using an
established label-free quantitative mass spectrometric
(LFQMS) method. This method described in detail else-
where [22, 23] uses individual three-dimensional align-
ment to determine peptide retention time using a
clustering method along with peptide ion peak areas cal-
culated from the extracted ion chromatogram (XIC)
generated by liquid chromatography - tandem mass
spectrometry (LC-MS/MS). Only two stone matrices
were analyzed in this study, by design. Our intent was to
1) improve and simplify the extraction of protein from
the stone powder and 2) apply a novel, more compre-
hensive LFQMS approach to identify and quantify as
many proteins as possible. The results indicate a stone
matrix proteome that is much larger and more complex
than previously observed.
Results and discussion
Stone extracts
It is not exactly clear what fraction of the total stone pro-
tein can be extracted in a form usable for proteomic ana-
lysis. Our extraction method yielded 7.20 μg protein/mg
stone powder for CaOx-Ia and 0.81 μg/mg for CaOx-Id.
The larger value is 3 times the average extraction yield
that we have previously reported for calcium oxalate
monohydrate (COM) stones using 9 M urea/1 mM DTT
[5]. The increased amount of protein in CaOx-Ia was
likely due to the presence of the x-ray lucent material
identified by micro CT. Note that most researchers, not
using micro CT, would likely be unable to detect the
presence of such a non-mineral-rich material, which, in
this case, clung tightly to the surface of stone fragments.
On the other hand, protein extraction from specimen
CaOx-Id yielded a value within the range we found previ-
ously for different COM stone specimens [5], though on
the low end of that range. The low yield of protein in this
specimen might be related to the tightly packed nature of
this form of COM stone (Fig. 1d).
The total amount of protein in these types of stones,
estimated from complete acid hydrolysis and measure-
ment of amino acids, has been reported to be about
17 μg/mg [2], but of course, such an acid hydrolysis de-
stroys protein identities. It is likely that a considerable
amount of stone protein is resistant to extraction by
solubilization methods that maintain protein primary
structure, as has been previously reported [5]. In com-
parison, of the previous studies where proteomic analysis
was used and extracted protein yields reported [7, 9, 17],
the average was 1.5 μg/mg, probably less than 10 % of
the total protein contained within the stones.
Whether the extraction resistant proteins are 1) very
low abundance components of the matrix proteome
trapped within the crystal matrix [15, 16] and thus not
detected by conventional means, 2) chemically more
hydrophilic and accordingly more avidly bound to crystal
surfaces, or 3) merely unextracted replicates of the pro-
teins identified below remains to be determined.
Label-free quantitative mass spectrometry
Using a label-free quantitative mass spectrometry plat-
form, we identified and quantified 1,059 unique protein
database (UniProt, http://www.uniprot.org) entries in-
cluding splice variants or isoforms (809 unique gene
names), in the two human kidney stone samples with a
false discovery rate (FDR) of ≤0.2 %. These proteins are
listed in a table in Additional file 1, along with their Uni-
Prot identities, gene symbols, protein names, and abun-
dances [22]. As illustrated in Fig. 2, 606 proteins were
common to both stone types; 70 proteins were unique to
CaOx-Ia, while 383 proteins were detected only in the
CaOx-Id stone powder. Specific peptide information for
all identified proteins and protein groups including pro-
tein coverage, # of unique sequences, # of identified pep-
tides, total # of identified sequences, is available in the
table found in Additional file 2.
To account for potential bacterial proteins within the
stone matrix, the MS data were searched against Coryne-
bacterium, Actinomyces, Lactobacillus jensenii, Streptococ-
cus anginosus, and Staphylococcus epidermidis protein
databases. No proteins were identified. This strongly sug-
gests that there is no significant bacterial contribution to
the stone matrix proteome in the specimens tested.
Since 2008, twelve papers have been published that de-
scribed various analyses of human kidney/bladder stone
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matrix proteomes or crystal-associated proteins [6–17].
Compared to those earlier investigations, we found the
kidney stone matrix proteome to be larger and much
more complex than observed previously. We identified
and quantified between 4–35 times as many proteins as
found in the other human studies. More specifically, we
found 259 proteins that were identified in earlier studies
(see the Human Kidney Stone Matrix Proteome Database
presented in Additional file 3), and also an additional 577
proteins not identified previously. This database also
contains the following information for each protein: iso-
electric point (pI), # of negatively charged residues (Asp +
Glu), # of positively charged residues (Arg + Lys), Neg/Pos
Ratio, aliphatic index, GRAVY score (grand average of
hydropathicity), molecular class, biological process, cellu-
lar component, and function.
The increased protein identification rate that we
achieved in this investigation may be due to two factors.
First, several previous studies used a demineralization ap-
proach to extract proteins from powdered stones that in-
cluded EDTA and/or SDS [7–9, 11, 13–17], both of which
were subsequently removed by either centrifugation or
dialysis steps. Boonla et al. [6] used a commercially avail-
able lithium dodecyl sulfate/glycerol solution at 100 °C to
extract proteins. Our use of 8 M urea/10 mM DTT with
sonication and two repeated overnight extractions of the
stone powder required no additional purification steps
Fig. 1 Representative pieces from the two stone specimens used.
a Fragment from CaOx-Ia, on mm-grid paper. b Micro CT slice
through fragment in A, showing pure calcium oxalate monohydrate
(COM). c Two stones from specimen CaOx-Id; stone on right has
shell broken off to reveal interior core, and on left is shell (top) and
core from another stone in this specimen. For CaOx-Id, only the shell
portions were collected for protein extraction. d Micro CT slice
through CaOx-Id stone, showing pure COM
Fig. 2 Venn diagrams showing the degree of overlap and exclusivity
of proteins identified and quantified in CaOx-Ia and CaOx-Id kidney
stone powders
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where proteins might be lost. As mentioned earlier, this
approach yielded, on average, more protein/mg of stone
powder than in previous studies. But that alone does not
account for the differences in the number of proteins
detected. A second reason may lie in the protein analysis
itself. Several previous studies used 1D and/or 2D gel elec-
trophoresis and subsequent LC-MS/MS or MALDI-MS/
MS to identify proteins in gel plugs [6, 11, 13, 14, 16, 17].
Others used LC-MS/MS or MALDI-MS/MS of whole ex-
tracts [7–10, 14–17], but used LC gradient profiles of
60 min or less to separate the tryptic peptides. Our use of
a 190 min LC gradient combined with the rapid scanning
features of the Orbitrap Velos Pro mass spectrometer
likely underlie our increased protein identification rate. It
should be noted that in a proteomic analysis of rat urinary
melamine stone matrix (where urea, thiourea, detergent
and DTT were used to extract proteins, a 90 min LC gra-
dient and a high resolution Orbitrap mass spectrometer
were used to separate and analyze tryptic peptides), over
1,000 proteins were identified [24].
Interestingly, there are 204 proteins listed in the data-
base in Additional file 3 that were identified in the previ-
ous twelve studies, but were not detected in our stone
samples. Nearly half of these are accounted for by 96
proteins (of 242) identified by Jou et al. in uric acid
stones [10]. The other 146 uric acid stone proteins they
detected were also identified in our CaOx stones. This
substantial dissimilarity likely is due to the physicochem-
ical differences between these various stone types and
the extraction methods and analytical approaches used.
Additionally, Merchant et al. analyzed the proteome of
CaOx stones obtained from human subjects and identi-
fied 158 proteins [14]. Forty-five of these were not de-
tected in our CaOx stones, suggesting that even within
similar stone types, the protein composition may be
patient-specific and thus differ significantly.
A brief, non-statistical comparison of CaOx-Ia and
CaOx-Id stone matrix protein composition is presented
below. At this point, it is important to restate that only
two stone matrices were analyzed in this study, by de-
sign, and that our intent was to 1) improve and simplify
the extraction of protein from the stone powder and 2)
apply a novel, more comprehensive LFQMS approach to
identify and quantify as many proteins as possible. The
following data analysis is by no means intended to imply
the existence of significant differences between the
unique CaOx stones. It is presented here to compare
and contrast the results of our new quantitative ap-
proach to previous stone matrix proteome studies and
not to make inferences on the pathophysiology of CaOx
stone formation.
The 50 most abundant proteins from each stone are
listed in Table 1. These correspond to many of the proteins
reported in previous studies, in particular: serum albumin,
apolipoproteins, calgranulins, osteopontins (10-12-fold
higher in CaOx-Id), prothrombin, alpha and beta
hemoglobin, neutrophil defensin I, complement proteins,
and alpha-1-antitrypsin. In contrast, proteins such as fatty
acid synthase and numerous cytokeratins were rarely ob-
served in previous studies. Their absence from previous
studies may be accounted for by the fact that these proteins
were not disclosed as their occurrence is generally thought
to be due to contamination from skin and ambient environ-
ment. This may be true of the epidermal and cuticular
keratins identified in this study (KRT2, KRT10, KRT31,
KRT77, KRT81 KRT84, KRT85), while others are well-
established components of epithelial cells throughout the
kidney [25–27] (KRT1, KRT3, KRT5, KRT6, KRT7, KRT8,
KRT9, KRT13, KRT14, KRT17, KRT18, KRT19, KRT31,
KRT80).
When one examines the database in Additional file 3,
of the 257 proteins reported in other papers that also
were found in our study, albumin, uromodulin (Tamm-
Horsfall Protein, THP), calgranulin-A (Protein S100-A8),
and calgranulin-B (Protein S100-A9) were common to
all studies. Albumin and THP were similarly abundant
in both our CaOx stones while calgranulin-A was nearly
ten-fold higher in CaOx-Ia. Lactotransferrin, osteopontin,
and prothrombin were detected in ten previous studies
and Vitamin K-dependent protein Z was detected in nine.
Twenty-two immunoglobulin-related proteins and 28
complement-related proteins were identified and quanti-
fied, and most were common to both of our CaOx
specimens.
Note that many of the proteins listed are undoubtedly
from blood or tissue, but this is also true for proteins
found in human urine [28]. Some work that has been
done on crystallization of calcium oxalate crystals
in vitro in human urine has suggested that proteins of
blood and tissue are not adsorbed to forming crystals,
with the idea that proteins of the blood or tissue are not
relevant to stone formation [29]. But simple crystal for-
mation is not the same as the formation of a stone, in
which the protein matrix plays an important role [30].
Moreover, injury to the renal papilla may be a normal
part of stone formation [31], so the presence of blood
and tissue proteins could well be a part of the formation
of a true stone.
Physicochemical analysis
Previous studies have considered the aggregate protein
charge and its potential connection to specific stone
types [7, 10]. In a comparison of 4 different stone types,
Canales et al. [7] failed to observe statistically significant
differences between the number of acidic- versus basic-
fractionated matrix proteins. In our study (Table 2), the
average pI of all proteins associated with the CaOx-Ia
stone or the CaOx-Id stone was similar (6.62 vs. 6.49),
Witzmann et al. Proteome Science  (2016) 14:4 Page 4 of 10
as was the average pI of all proteins unique to CaOx-Ia
or CaOx-Id stones (6.75 vs. 6.33). In comparison, a slightly
more alkaline average pI of 7.2 has been observed in uric
acid stone matrix proteins [10]. Conclusive comparison of
these and other properties requires additional samples
and further study. Nevertheless, negative amino acid/posi-
tive amino acid ratios, aliphatic indices (a measure of pro-
tein stability) and GRAVY scores were similar across all
comparisons in the CaOx stones. The mean GRAVY
scores, all considerably negative, indicate overall protein
hydrophilicity.
Bioinformatic analysis
Of the proteins listed in the Human Kidney Stone
Matrix Proteome Database (Additional file 3), 680
(82 %) have been detected in kidney cells or tissue (per
the Human Proteome Map), 154 (18 %) have not been
detected in kidney, so their origin may be considered
“extra-renal”, 144 (17 %) are considered to be moder-
ately or highly abundant in kidney, 248 (30 %) are con-
sidered to be in the “extracellular component” (kidney
or otherwise), and 75 (9 %) are considered to be “cyto-
skeletal and/or structural” proteins.
Proteins identified in the CaOx stones also represented
a broad variety of molecular classes (Table 3). The distri-
bution of classes reflects the prevalence of “cellular
proteins” in the matrix, dominated by cytoskeletal & as-
sociated proteins, structural proteins, transport/cargo
proteins, chaperone/heat shock proteins, and ribonu-
cleoprotein/RNA binding proteins, rather than an excess
of urine- or plasma-related proteins. Many of these pro-
teins may stem from the considerable cellular compo-
nents of stone matrices first observed by Boyce in 1956
[32]. Nevertheless, as Table 1 and Additional file 1 indi-
cate, the individually most abundant proteins in the
Table 1 Fifty most-abundant proteins in kidney stones CaOx-Ia
and CaOx-Id
CaOx-Ia CaOx-Id
Hemoglobin subunit beta Prothrombin
Neutrophil defensin 1
(Defensin, Alpha 1)
Hemoglobin subunit beta
Hemoglobin subunit alpha Hemoglobin subunit alpha
Protein S100-A9 (Calgranulin-B) Thrombin light chain
Complement C3 Vitronectin
Hemoglobin subunit delta Complement C3
Protein S100-A8 (Calgranulin-A) Vitamin K-dependent protein Z
Alpha-1-antitrypsin Plasminogen
Keratin, type I cytoskeletal 10 Keratin, type I cytoskeletal 10
Prothrombin Serum albumin
Fibrinogen beta chain Hemoglobin subunit delta
ATP-dependent RNA helicase A C4b-binding protein alpha chain
Apolipoprotein A-IV Alpha-1-antitrypsin
Keratin, type I cytoskeletal 13 Keratin, type II cytoskeletal 1
Serum albumin Fatty acid synthase
Keratin, type II cytoskeletal 1 Apolipoprotein A-I
Keratin, type I cytoskeletal 9 Mannan-binding lectin serine
protease 2
Fatty acid synthase Osteopontin, Isoform 5
Nucleolin Myosin-9
Apolipoprotein B-100 Heat shock protein beta-1
Heparin cofactor 2 Fibroleukin (fibrinogen-like 2)
Actin, cytoplasmic 1 Apolipoprotein D
Fibrinogen alpha chain Histidine-rich glycoprotein
Plasminogen Tubulin beta chain
Profilin-1 Fibrinogen beta chain
Eosinophil cationic protein Kininogen-1, Isoform LMW
Coagulation factor XII Keratin, type I cytoskeletal 9
Complement C4-A Heat shock protein HSP 90-beta
Complement C4-B Apolipoprotein B-100
Vitronectin Pro-epidermal growth factor
Myosin-9 Fibrinogen alpha chain
Apolipoprotein A-I Neutrophil defensin 1
(Defensin, Alpha 1)
Leukocyte elastase inhibitor Extracellular superoxide dismutase
[Cu-Zn]
Alpha-2-macroglobulin Argininosuccinate synthase
Apolipoprotein D Heparin cofactor 2
Thrombin light chain Complement factor B
Complement factor B Keratin, type I cytoskeletal 19
Histone H4 Apolipoprotein A-IV
Vesicular integral-membrane
protein VIP36
Complement C4-A
Fibrinogen gamma chain Coagulation factor X
Table 1 Fifty most-abundant proteins in kidney stones CaOx-Ia
and CaOx-Id (Continued)
Serum paraoxonase/arylesterase 1 Complement C4-B
Peroxiredoxin-2 Vesicular integral-membrane
protein VIP36
Complement C5 Actin, cytoplasmic 1
Complement component C9 Profilin-1
WD repeat-containing protein 1 Nucleolin
Antithrombin-III Keratin, type II cytoskeletal 7
Mannan-binding lectin serine
protease 2
Protein S100-A9 (Calgranulin-B)
Mannosyl-oligosaccharide
1,2-alpha-mannosidase IA
Osteopontin, Isoform B
Vitamin K-dependent protein S Mannosyl-oligosaccharide
1,2-alpha-mannosidase IA
Keratin, type II cytoskeletal 2 Antithrombin-III
Proteins listed in order of abundance
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CaOx stone matrix are blood/plasma derived – and pre-
sumably urine – proteins.
The following calcium binding proteins were detected:
annexins A1, A2, A3, A4, A5, A9, A10, and A11; calcy-
phosin; calmodulin; calsequestrin-2; cilaggrin-2; cucle
obindin-1; osteopontin; Profilaggrin; Protein S100-A2
(S100 calcium-binding protein A2); Protein S100-A6
(Calcyclin); Protein S100-A7 (Psoriasin); Protein S100-
A8 (Calgranulin-A); Protein S100-A9 (Calgranulin-B);
Protein S100-P (Migration-inducing gene 9 protein);
Protein S100-A11 (Calgizzarin); and Protein S100-A12
(Calgranulin-C), and these may have implications in the
mineralization process [33, 34]. Additionally, the fol-
lowing urinary proteins known to have the potential
to modulate crystal formation and retention [35–37]
were identified and quantified as prominent constitu-
ents of the stone matrix: Tamm-Horsfall protein;
osteopontin; Α-1 microglobulin; calprotectin (protein
S100-A8 & 9); serum albumin; prothrombin; inter-α
trypsin inhibitor (heavy chains H1, H2, and 4);
heparin sulphate proteoglycan; bikunin; CD44, fetuin,
and various collagens.
As in two previous studies [10, 14] where inflammatory,
coagulation, cell adhesion, and acute-phase response path-
ways were directly related to high abundance matrix pro-
teins, we used pathway analysis to predict with statistical
confidence which pathways might be associated with the
matrix proteins identified and quantified in our CaOx
stones. These results (79 unique pathways) are presented
in the Pathway Data found in Additional file 4. Some of
the most statistically significant pathways included LXR/
RXR activation, coagulation system, acute phase response
signaling, FXR/RXR activation, clathrin-mediated endo-
cytosis signaling, intrinsic prothrombin activation path-
way, epithelial adherens junction signaling/remodeling,
extrinsic prothrombin activation, complement system,
and the production of nitric oxide and reactive oxygen
species in macrophages. Analogous observations were
made via functional annotation clustering of the CaOx
proteins presented in the Functional Annotation Clusters
found in Additional file 5, where inflammatory response
and immune related functions were most notable and
cytoskeletal structural molecule activity, extracellular
glycoprotein signaling, wound healing, coagulation, and
regulation of body fluid levels annotations were signifi-
cantly represented.
Conclusions
The proteomic data presented here corroborate and sig-
nificantly expand previous observations of the kidney
stone matrix protein composition, revealing a more
complex matrix proteome than previously reported for
human kidney stones of any type. It remains unclear as
to whether the identified proteins, their physicochemical
properties, and their associated pathways/functions are
directly related to mechanisms of stone formation or
simply coincident and accumulated through long-term
exposure of the growing stone to urine flow. Nonethe-
less, the comprehensive approach we have developed
and reported here will enable us and others to address
such questions by analyzing and comparing comprehen-
sive protein profiles in a broad range of stone types in
relatively small stone specimens from individual patients
who are carefully stratified by phenotype, and for whom
important clinical data are known.
Methods
Reagents
Urea, DL-Dithiothreitol (DTT), triethylphosphine (TEP),
iodoethanol, and ammonium bicarbonate (NH4HCO3)
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). LC-MS grade acetonitrile (ACN) with 0.1 % formic
acid (v/v) and water (H2O) with 0.1 % formic acid (v/v)
were purchased from Burdick & Jackson (Muskegon, MI,
USA). Modified sequencing grade porcine trypsin was ob-
tained from Princeton Separations (Freehold, NJ, USA).
All other reagents used were of the highest quality
available.
Stone specimens, preparation of stone matrix protein
extracts, and protein assay
Stones were de-identified specimens analyzed as pure
COM and obtained from a stone analysis laboratory (Beck
Analytical Services, Indianapolis IN). They were chosen so
that several grams of material were available within a single
specimen. The specimens were scanned using micro CT
(SkyScan 1172, Bruker, Kontich, Belgium) to assess overall
mineral purity, and mineral composition was confirmed
using Fourier-transform infrared spectroscopy [38].
Figure 1 shows representatives of the two specimens
used in the present study. The specimen named CaOx-Ia
consisted of multiple fragments of COM that mostly had
the morphological form Ia, which indicates a tightly
Table 2 Physicochemical characteristics of stone matrix proteomes
Isoelectric Point Neg/Pos Ratio Aliphatic Index GRAVY Score
CaOx-Ia All Proteins 6.62 ± 1.65 1.16 ± 0.66 79.07 ± 11.17 −0.416 ± 0.229
CaOx-Id All Proteins 6.49 ± 1.65 1.19 ± 0.60 78.92 ± 11.42 −0.438 ± 0.240
CaOx-Ia Only 6.75 ± 1.71 1.08 ± 0.39 80.14 ± 12.26 −0.340 ± 0.171
CaOx-Id Only 6.33 ± 1.65 1.20 ± 0.39 78.97 ± 15.16 −0.458 ± 0.348
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packed COM form that typically is dark brown in color
[21]. The CaOx-Ia specimen also contained some x-ray
lucent material, identified by infrared spectroscopy to be
non-mineralized protein. Specimen CaOx-Id was also
pure COM, but consisted of a dozen smooth stones of the
morphological form Id, a distinctly different but still
tightly packed form of COM [21]. Note that CaOx-Id, due
to its morphology, contained no extraneous protein, as
did CaOx-Ia. It may also be noteworthy that neither of
these CaOx specimens contained any apatite that was vis-
ible by micro CT (a very sensitive method for detecting
this mineral [38]). Thus, these CaOx specimens were not
representative of the kinds of stones that would arise from
growth on Randall's plaque [4].
CaOx-Ia and CaOx-Id stones were powdered by hand in
small portions using an agate mortar and pestle, grinding
the powder to the consistency of fine flour. The portions
of powder for each specimen were combined and thor-
oughly mixed. Aliquots of these stone powders (300 mg)
were combined with 1 mL of freshly prepared 8 M urea
and 10 mM DTT by vortex mixing (15 s) in Fisherbrand™
skirted microcentrifuge tubes with threaded ends (Catalog
No. 02-681-343). The suspension was sonicated (Micro-
son™, Misonix, USA) by 10 intermittent 1 s microprobe
pulses at an energy output of 15 W, every 30 min for 4 h
at room temperature. The tubes were incubated at room
temperature overnight on an orbital shaker (200 rpm),
vortexed, and subjected to one more sonication step as
described above. The suspension was centrifuged at 3,200
x g for 1 h at room temperature (Jouan GR4i centrifuge,
ThermoFisher Scientific, USA). The supernatant was col-
lected and the pellet subjected to a second protein extrac-
tion carried out exactly as the first. Extracts were
combined and protein concentration in each pooled
extract (~2 mL) was determined by the Bradford assay
[39]. The solubilized protein extracts were then stored at
−80 °C until LFQMS analysis.
Proteolysis and LC-MS/MS
A 100 μg aliquot of each sample was concentrated using
the Vivaspin® 500 Centrifugal Concentrator (Vivaproducts,
USA) by centrifugation at 8,000 rpm. The volume of each
sample was adjusted to 200 μL (4 M urea) and then re-
duced and alkylated by triethylphosphine and iodoethanol
as previously described [40]. Briefly, 200 μL of the reduc-
tion/alkylation cocktail was added to the protein solution.
The sample was incubated at 35 °C for 60 min, dried by a
Vacuum Concentrator Centrifugal System (RC 10.10,
Jouan), and reconstituted with 100 μL of 100 mM
NH4HCO3 at pH 8.0. A 150 μL aliquot of a 20 μg/mL
trypsin solution was added to the sample and incubated at
35 °C for 3 h, after which another 150 μL of trypsin was
added, and the solution incubated at 35 °C for an
additional 3 h.
Sample digests were analyzed using a ThermoScientific
Orbitrap Velos Pro hybrid ion trap-Orbitrap mass spec-
trometer coupled with a Surveyor autosampler and MS
HPLC system (ThermoScientific). Tryptic peptides were
injected as technical replicates onto a C18 reversed phase
column (TSKgel ODS-100 V, 3 μm, 1.0 mm × 150 mm) at
Table 3 Representation of CaOx stone proteins by molecular
class (≥5)
Protein Molecular Class # of unique proteins
identified
Cytoskeletal & associated protein; structural
protein
75
Transport/cargo protein 49
Chaperone/Heat shock protein 36
Ribonucleoprotein; RNA binding protein 35
Extracellular matrix protein 31
Transcription factor or regulatory protein 29
Enzyme: Hydrolase 27
Translation regulatory protein 27
G protein; GTPase & associated 26
Immunoglobulin 24
Unclassified 24
Ribosomal subunit 23
Adhesion molecule 21
Enzyme: dehydrogenase 21
Ubiquitin proteasome system 21
Complement protein 20
Protease inhibitor 19
Adapter molecule 18
Calcium binding protein 18
Secreted polypeptide 18
Coagulation factor 16
Cysteine protease 15
DNA binding protein 15
Integral membrane protein 15
Serine/threonine kinase or phosphatase 15
Enzyme: Ligase 14
Enzyme: Oxidoreductase 14
Cell surface receptor 12
Enzyme: Phosphotransferase 12
Serine protease 9
Enzyme: Isomerase 7
Enzyme: Peroxidase 6
Membrane transport protein 6
MHC complex protein 6
ATPase 5
Enzyme: Reductase 5
Witzmann et al. Proteome Science  (2016) 14:4 Page 7 of 10
a flow rate of 50 μL/min. The mobile phases A, B, and C
were 0.1 % formic acid in water, 50 % ACN with 0.1 % for-
mic acid in water, and 80 % ACN with 0.1 % formic acid
in water, respectively. The gradient elution profile was as
follows: 10 % B (90 % A) for 7 min, 10–67.1 % B (90–
32.9 % A) for 163 min, 67.1-100 % B (32.9-0 % A) for
10 min, and 100-50 % B (0-50 % C) for 10 min. It is im-
portant to note that the 190 min elution gradient used in
this analysis is much longer than conventional 60 min elu-
tion profiles used in previous kidney stone proteome stud-
ies [7–10, 14–17] where LC-MS/MS was used, and likely
accounts for much of the significant improvement in
proteome coverage observed here (see Results and
Discussion).
The data were collected in the “Data dependent MS/
MS” mode of Fourier transform-ion trap (MS-MS/MS)
with the electrospray ionization interface using normal-
ized collision energy of 35 % (collision induced dissoci-
ation). Dynamic exclusion settings were set to repeat
count = 1, repeat duration = 30 s, exclusion duration =
45 s, and exclusion mass width = 10 ppm (low) and
10 ppm (high).
Protein Identification and ouantification
The acquired data were searched against the UniProt
protein sequence database of HUMAN (released on
07/09/2014) using X!Tandem algorithms in the Trans-
Proteomic Pipeline (TPP, v. 4.6.3) (http://tools.proteo-
mecenter.org/software.php). General parameters were
set to: parent monoisotopic mass error set as 10 ppm,
cleavage semi set as yes, missed cleavage sites set at 2, and
static modification set as + 44.026215 Da on Cysteine. The
peptide and protein identifications made by X!Tandem
were validated by PeptideProphet [41] and ProteinProphet
[42] in the TransProteomic Pipeline (http://tools.proteo-
mecenter.org). Only validated proteins and peptides with
protein probability ≥ 0.9000 and peptide probability ≥
0.8000 were reported. False discovery rate (FDR) was esti-
mated by a nonparametric concatenated randomized
target-decoy database search [43]. As mentioned earlier,
for this experiment and those TPP settings, protein identi-
fication FDR was ≤0.2 %.
Protein quantity was determined using an in-house
label-free quantification software package, IdentiQuantXL
[22], developed to individually and accurately align the re-
tention time of each peptide and to apply multiple filters
for exclusion of unqualified peptides to enhance label-free
protein quantification. As previously described in detail
[22], peptide retention time determination using cluster-
ing, extraction of peptide intensity using MASIC [44],
peptide coefficient of variation calculation, and peptides
correlation were all conducted within the software plat-
form to “filter out” unqualified peptides. Using only quali-
fied peptides, protein intensity was calculated using the
formula: Protein Intensity = (intensity of peptide 1)/(pep-
tide 1 sharing times) +… + (intensity of peptide n)/(pep-
tide n sharing times). For a peptide shared by different
proteins, the intensity of this peptide was divided by the
number of times the peptide was shared.
Validation of protein identity and quantity
Results of the LFQMS analysis were validated immuno-
logically for beta-2-microglobulin, calbindin, clusterin,
cystatin-C, glutathione S-transferase P, neutrophil gelatin
ase-associated lipocalin, and osteopontin. CaOx-Ia and
CaOx-Id protein extracts were processed on a Bio-Plex 200
System with High Throughput Fluidics (HTF) Multiplex
Array System (Bio-Rad Laboratories, Hercules, CA). The
proteins were quantified simultaneously using Bio-Plex
Pro™ RBM Human Kidney Toxicity Assays (panels 1 and 2)
on the Bio-Plex 200 system (BIO-RAD, USA) according to
manufacturer instructions. Results were compared to
LFQMS data as the ratio between CaOx-Ia/CaOx-Id and
these data are listed in Table 4.
Physicochemical properties of matrix proteins
Grand average of hydropathicity (GRAVY) scores, ali-
phatic indices, and number of negatively (Asp and Glu)
and positively (Arg and Lys) charged residues for all
identified proteins were calculated using the Protein
Identification and Analysis Tools (ProtParam) on the
ExPASy Server (http://web.expasy.org/protparam/) [45].
The GRAVY score for a peptide or protein is calculated
as the sum of hydropathy values of all the amino acids,
divided by the number of residues in the sequence. The
aliphatic index of a protein is defined as the relative vol-
ume occupied by aliphatic side chains (alanine, valine,
isoleucine, and leucine) and may be regarded as a posi-
tive factor for increased thermostability of globular
proteins.
Bioinformatic analysis
To investigate the functional relevance of the proteins
identified and quantified in the two stones, we used two
common bioinformatic tools. Protein gene-symbol lists
were uploaded onto the Ingenuity Pathway Analysis (IPA)
Table 4 Validation of LFQMS Results: CaOx-Ia/CaOx-Id Ratio
Protein LFQMS ELISA
Beta-2-microglobulin 0.7 0.2
Calbindin NDa NDa
Clusterin 0.4 0.2
Cystatin-C 0.1 0.4
Glutathione S-transferase P 0.9 0.9
Neutrophil gelatinase-associated lipocalin ND# 8.5
Osteopontin, Isoform 5 0.1 0.1
NDa = not detected in either stone; ND# = not detected in CaOx-Id
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software server (http://www.ingenuity.com) (Qiagen, US)
and analyzed using the Core Analysis module to rank
stone-specific proteins into canonical pathways in a statis-
tically significant manner. Additionally, UniProt identifiers
were submitted to the Human Proteome Map (http://
www.humanproteomemap.org) [46], GeneCards® (http://
www.genecards.org) [47], and the Gene Ontology (GO)
database (http://go.princeton.edu/cgi-bin/GOTermMap-
per) [48] via Generic Gene Ontology (GO) Term Mapper
for information regarding each protein’s molecular class,
biological process, cellular component, tissue specificity,
and function.
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Additional file 1: Protein quantitation data for 1,059 human kidney
stone proteins. (PDF 418 kb)
Additional file 2: Peptide sequence/Protein Identification, mass spectral
data for 5,957 peptides. (PDF 3099 kb)
Additional file 3: Human Kidney Stone Matrix Proteome Database –
1,039 proteins found in human kidney stone matrices from this study
and 12 other proteomic papers. Includes details regarding Isoelectric
Point, negatively charged residues (Asp + Glu), positively charged residues
(Arg + Lys), Neg/Pos Ratio, Aliphatic index, GRAVY score, Molecular Class,
Biological Process, Cellular component, and Function. (PDF 316 kb)
Additional file 4: Ingenuity Pathway Analysis Results - Canonical
Pathways associated with Kidney stone matrix proteins. (PDF 60 kb)
Additional file 5: Functional Annotation Clustering of kidney stone
matrix proteins obtained from the DAVID database. (PDF 100 kb)
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